Generic and innovative drugs market in Central Europe 2011

The report is a comprehensive analysis of six countries of Central Europe:

• Poland
• Romania
• Slovakia
• Czech Republic
• Hungary
• Bulgaria.

It provides a characteristic of generic and innovative medicines segments, with forecasts for years 2011-2013. The report is supplemented with a detailed description of factors influencing these segments, especially reimbursement policies, pricing policies, drug patent expiry and data exclusivity periods in particular countries. Countries’ policies description in the area of counterfeit medicines as well as profiles of largest generic and innovative drug manufacturers on the regional scale are also included in this publication. 

Why did we decide to write this report?

• there is no such report on the market (which analyses and compares 6 CE countries)
• aim to show how the economic crisis affected the generic market in particular countries as well as overall in the region
• aim to show how the economic crisis affected the innovative market in particular countries as well as overall in the region

Key report's sections

• value of the generic drugs market in Central Europe 2007-2013
• value of innovative drugs market in Central Europe 2007-2013
• market size of generic drugs market in particular countries and development forecasts for 2011-2013
• market size of innovative drugs market in particular countries and development forecasts for 2011-2013
• market share of generic/innovative drugs market in CE and in particular countries
• patients and doctors attitudes towards generic and innovative medicines
• regulations regarding prices of non-reimbursed and reimbursed medicines
• VAT rates on medicines
• average and official mark-ups for medicines
• reimbursement system
• reimbursement process
• future changes on the generic and innovative drug markets as well as in the reimbursement segment
• latest and expected changes on reimbursement lists
• drug patent expiry and data exclusivity periods, including SPCs
• best-selling generic and innovative medicines
• largest generic and innovative drug manufactures in particular countries and in the CE region as a whole
• counterfeit medicines – market share, country policies and many more

The report answers following questions

• What is the value of the generic and innovative drugs market in Central Europe 2007-2013?
• What is the market size of generic and innovatgive drugs market in particular CE countries?
• In which countries will the generic drugs market develop the fastest between 2011 and 2013?
• In which countries will the innovative drugs market develop the fastest between 2011 and 2013?
• What are patients and doctors attitudes towards generic and innovative medicines?
• What are regulations regarding prices of non-reimbursed and reimbursed medicines in CE countries?
• How does the reimbursement system function in particular CE countries?
• How does the reimbursement process look like in particular countries?
• What changes can be expected in the future on the generic and innovative drugs market as well as in the reimbursement segment?
• Which medicines were recently included on/removed from reimbursement lists in particular CE countries?
• What changes on the reimbursement lists of medicines can be expected in CE countries in the nearest future?
• What are the drug patent expiry periods in particular CE countries?
• For which medicines Supplementary Protection Certificates are to expire in CE in the nearest future?
• What are the data exclusivity periods in particular countries?
• Which are the best-selling generic and innovative medicines in CE?
• Who are the largest generic and innovative drugs manufactures in particular countries and in the CE region as a whole?

Report strengths

• detailed characteristic of six CE countries together with a comparative analysis of them
• development forecasts for generic and innovative drugs market for 2011-2013
• wide scope of analysis, including reimbursement policies, pricing policies and many more
• all the necessary information regarding generic and innovative drugs markets in CE in one publication for a competitive price

Extract from this report

• In 2011 and 2012 the trends which boosted generic sales in 2010, including price pressure and other restrictive measures, will continue. This is why the generic market will develop more rapidly than its original counterpart in these years .
• Despite some advances in recent years, access to healthcare innovations such as latest generation therapies or modern diagnostic equipment is seriously insufficient in Poland and remains a major challenge for the country’s healthcare system .
• According to companies present on the market, there is not much space for investments and launching new drugs on the Czech pharmaceutical market. Also, in 2010 the climate for manufacturers of prescription drugs reimbursed from the public health insuranc e funds, was not amiable. It refers to the market-wide 7% cuts in the drug prices introduced on 1 January 2010 and further drug reimbursement reviews that in majority cases reduced either the maximum drug prices and/or their reimbursements. 

Market commentary by expert

According to our estimates, in 2010 the generic drug market in Central Europe increased by 12%, whereas that of original medicines grew at a rate of around 10% in euro terms. In the coming years, the rate of growth for generic medicines may also be higher than that for the innovative drug sector. The trends which boosted generic sales in 2010, being a result of countries’ cost-saving policies, including price pressure and other restrictive measures, will since continue.

Agnieszka Stawarska, Pharmaceutical Market Analyst
Monika Stefańczyk, Head Pharmaceutical Market Analyst 

Request sample pages/interactive screenshare

To receive more information on this report, please sign up.

*required

*Would you like a FREE interactive screenshare?		Yes No
*Email:
		To make sure you receive the requested information, add info@pmrcorporate.com to your company trusted emails. Contact your IT department for details.
*Your company core business:		IT, Telecoms Construction Pharma, Healthcare Retail, FMCG Finance, Investments, Banking Consulting, Research, Law Government, Trade Organisations Media, Publications Education, Students Other
		Privacy Policy
		I agree with terms and conditions of PMR Privacy Policy. SUBSCRIBE

1. Report methodology p. 13

2. Executive summary p. 17

3. Characteristics of generic and innovative drug markets in Central European countries p. 27

   • Comparative analysis p. 27
     • Prices of generic and innovative drugs p. 27
     • Market value between 2008 and 2013 p. 30
     • Average CAGR for generic and innovative drug markets in CE countries 2011-2013 p. 32
     • Market share of generic and innovative medicines p. 33
   • Poland p. 35
     • Main trends and events on generic and innovative drug market p. 35
     • Market size p. 39
     • Share of pharmaceutical market p. 39
     • Market forecasts for 2011-2013 p. 42
     • Attitudes toward generic and innovative drugs p. 43
   • Czech Republic p. 43
     • Main trends and events on generic and innovative drug market p. 43
     • Market size p. 48
     • Share of pharmaceutical market p. 49
     • Market forecasts for 2011-2013 p. 50
     • Attitudes toward generic and innovative drugs p. 52
     • Generic substitution at pharmacies p. 52
   • Romania p. 53
     • Main trends and events on generic and innovative drug market p. 53
     • Market size p. 58
     • Share of pharmaceutical market p. 58
     • Market forecasts for 2011-2013 p. 59
   • Hungary p. 61
     • Main trends and events on generic and innovative drug market p. 61
     • Market size p. 64
     • Share of pharmaceutical market p. 65
     • Market forecasts for 2011-2013 p. 66
     • Attitudes toward generic and innovative drugs p. 66
     • Patients p. 66
     • Pharmacists p. 67
     • Doctors p. 68
   • Slovakia p. 69
     • Main trends and events on generic and innovative drug market p. 69
     • Market size p. 72
     • Share of pharmaceutical market p. 72
     • Market forecasts for 2011-2013 p. 73
   • Bulgaria p. 75
     • Main trends and events on generic and innovative drug market p. 75
     • Market size p. 79
     • Share of pharmaceutical market p. 81
     • Market forecasts for 2011-2013 p. 81

4. Best-selling drugs in Central Europe p. 83

   • Poland p. 83
     • Best-selling drugs p. 83
     • Drug patent expiry and data exclusivity periods p. 84
   • Czech Republic p. 85
     • Best-selling drugs p. 85
     • Best-selling substances p. 87
     • Drug patent expiry and data exclusivity periods p. 88
   • Romania p. 90
     • Best-selling drugs p. 90
     • Drug patent expiry and data exclusivity periods p. 91
   • Hungary p. 92
     • Best-selling drugs p. 92
     • Drug patent expiry and data exclusivity periods p. 93
   • Slovakia p. 96
     • Best-selling drugs p. 96
     • Drug patent expiry and data exclusivity periods p. 97
   • Bulgaria p. 98
     • Best-selling drugs p. 98
     • Drug patent expiry and data exclusivity periods p. 106
   • Comparative analysis of drug patent expiry and data exclusivity periods in CE p. 107

5. Counterfeit products p. 109

   • Poland p. 109
   • Czech Republic p. 110
   • Romania p. 110
   • Hungary p. 111
   • Slovakia p. 111
   • Bulgaria p. 111

6. Reimbursement and pricing policies in Central Europe p. 113

   • Poland p. 113
     • Pricing policies p. 113
       • VAT rate p. 113
       • Non-reimbursed drugs on pharmacy market p. 113
       • Reimbursed drugs on pharmacy market p. 114
       • Drugs on hospital market p. 115
     • Reimbursement policies p. 115
       • Reimbursement system p. 115
       • Reimbursement process p. 116
       • Reimbursement spending p. 116
       • Reimbursement reform p. 122
       • Latest changes to reimbursement lists p. 123
       • Expected changes to reimbursement lists p. 126
   • Czech Republic p. 127
     • Pricing policies p. 127
       • General trends p. 127
       • VAT rate p. 128
       • Non-reimbursed drugs on pharmacy market p. 128
       • Reimbursed drugs on pharmacy market p. 128
       • Drugs on hospital market p. 130
       • Co-payment p. 130
     • Reimbursement policies p. 131
       • Reimbursement system p. 131
       • Reimbursement process p. 132
       • Reimbursement spending p. 133
       • Latest changes to reimbursement lists p. 134
   • Romania p. 136
     • Pricing policies p. 136
       • General trends p. 136
       • VAT rate p. 136
       • Non-reimbursed drugs on pharmacy market p. 136
       • Reimbursed drugs on pharmacy market p. 137
       • Drugs on hospital market p. 138
     • Reimbursement policies p. 138
       • Reimbursement system p. 138
       • Reimbursement process p. 139
       • Reimbursement spending p. 139
       • Reimbursement reform p. 141
       • Latest changes to reimbursement lists p. 142
   • Hungary p. 143
     • Pricing policies p. 143
       • VAT rate p. 143
       • Other taxes p. 143
       • Non-reimbursed drugs on the pharmacy market p. 145
       • Reimbursed drugs on pharmacy market p. 145
       • Drugs on hospital market p. 146
       • Generic drugs p. 146
       • Generic programme p. 147
       • Semmelveiss Plan p. 148
     • Reimbursement policies p. 149
       • Reimbursement system p. 149
       • Reimbursement process p. 150
       • Reimbursement spending p. 151
       • Latest changes to reimbursement lists p. 153
       • Expected changes to reimbursement lists p. 155
   • Slovakia p. 156
     • Pricing policies p. 156
       • VAT rate p. 156
       • Non-reimbursed drugs on pharmacy market p. 156
       • Reimbursed drugs on pharmacy market p. 156
       • Drugs on hospital market p. 157
       • Generic substitution p. 158
     • Reimbursement policies p. 158
       • Reimbursement system p. 158
       • Reimbursement process p. 159
       • Reimbursement reform p. 160
       • Latest changes to reimbursement lists p. 164
   • Bulgaria p. 168
     • Pricing policies p. 168
       • VAT rate p. 168
       • Non-reimbursed drugs on pharmacy market p. 168
       • Reimbursed drugs on pharmacy market p. 169
       • Drugs on hospital market p. 169
     • Reimbursement policies p. 170
       • Reimbursement system p. 170
       • Reimbursement process p. 171
       • Reimbursement of medicines for rare and contagious diseases p. 172
       • Reimbursement spending p. 173
       • Latest changes to reimbursement lists p. 175

7. Key manufacturers p. 179

   • Profiles of selected leading generic drug manufacturers in CE p. 179
   • Profiles of selected leading innovative drug manufacturers in CE p. 213
   • Key players in selected CE countries p. 256
     • Poland p. 256
     • Czech Republic p. 261
     • Romania p. 263
     • Hungary p. 270
     • Slovakia p. 271
     • Bulgaria p. 272

8. List of graphs p. 273

9. List of tables p. 279

10. About PMR p. 283

11. Contact PMR p. 284

List of graphs

1. Market value (€ bn) and y-o-y change of the generics drug market 1. in Central Europe, 2008-2013
2. Market value (€ bn) and y-o-y change of the original drug market 2. in Central Europe, 2008-2013
3. CAGR for generics drug markets in the countries analysed, 2011-20133.
4. CAGR for innovative drug markets in the countries analysed, 2011-20134.
5. Average price per standard drug unit (€) in CE countries in comparison with 5. other countries, Q1 2009-Q1 2010
6. Average price per standard drug unit (€) for generic and original medicines 6. in CE countries in comparison with other countries, retail and hospital sales, Q2 2008-Q2 2009
7. Average price per standard drug unit (€) of generic and original medicines 7. in CE countries in comparison with other countries, retail sales, Q3 2009
8. Market value (€ bn) and y-o-y change of the generics drug market 8. in Central Europe, 2008-2013
9. Market value (€ bn) and y-o-y change of the original drug market 9. in Central Europe, 2008-2013
10. CAGR for generics drug markets in the countries analysed, 2011-201310.
11. CAGR for innovative drug markets in the countries analysed, 2011-201311.
12. Share of generic drugs as a proportion of the overall pharmaceutical market 12. in the CE countries analysed, by value, Q3 2009
13. Share of generic drugs as a proportion of the overall pharmaceutical market 13. in CE countries, by volume, Q3 2009
14. Breakdown of medicines which are not patent-protected in selected CE countries 14. in comparison with other countries, by volume, April 2009-March 2010
15. Value (PLN bn) and increase in sales of foreign medicines in Poland, 15. 2000-2010
16. Value (PLN bn) and increase in sales of domestic medicines in Poland, 16. 2000-2010
17. Share of generic and innovative drugs as a proportion of overall pharmaceutical 17. market in Poland, by value, Q2 2009-Q1 2010
18. Share of generic and innovative drugs as a proportion of overall pharmaceutical 18. market in Poland, by volume, Q2 2009-Q1 2010
19. Share of generic and innovative drugs as a proportion of Rx pharmaceutical 19. market in Poland, by value, 2004-April 2010
20. Share of generic and innovative drugs as a proportion of Rx pharmaceutical 20. market in Poland, by volume, 2004-April 2010
21. Value (€ bn) and y-o-y change in the Polish generic drugs market, 21. 2007-2013
22. Value (€ bn) and y-o-y change in the Polish innovative drugs market, 22. 2007-2013
23. Reduction in ex-factory medicine prices in the Czech Republic, 23. by category of product, 2010
24. Estimated market value (CZK bn) of generic and innovative medicines 24. in the Czech Republic, 2008-2009
25. Share of generic and innovative medicines on the Czech retail 25. and hospital market, by volume, April 2008-March 2009
26. Share of generic and innovative medicines as a proportion of the Czech 26. pharmaceutical market, by value and volume, Q1 2010
27. Breakdown of Rx medicines not patent-protected in the Czech Republic, 27. in volume terms, April 2009-March 2010
28. Value (€ m) and y-o-y change in the Czech generic drug market, 2004-201328.
29. Value (€ m) and y-o-y change in the Czech innovative drug market, 29. 2004-2013
30. Attitudes of patients and pharmacists toward generic substitution at pharmacies 30. in the Czech Republic, 2008
31. Attitudes of patients and pharmacists toward generic substitution at pharmacies 31. in the Czech Republic, 2009
32. Number of products withdrawn from the market in Romania, 32. by product status, 2009
33. Number of drugs in parallel export from Romania, 2007-200933.
34. Share of the largest companies on the antidepressant market in Romania, 34. by value, H1 2010
35. Estimated share of generic and innovative drugs as a proportion of overall 35. pharmaceutical market in Romania, by value, 2008 and 2010
36. Estimated share of generic and innovative drugs as a proportion of overall 36. pharmaceutical market in Romania, by volume, 2009
37. Value (€ m) and y-o-y change in the Romanian generic drugs market, 37. 2008-2013
38. Market value (€ m) and y-o-y change in the Romanian innovative drug market, 38. 2008-2013
39. The total and export revenues of pharmaceutical manufacturers in Hungary 39. (HUF bn), 2000-2009
40. Number of imported and domestic pharmaceutical products in Hungary, 40. 2000-2008
41. Share of generic and innovative drugs as a proportion of overall pharmaceutical 41. market in Hungary, by value, Q3 2009
42. Breakdown of non-patent protected Rx medicines in Hungary, by volume, 42. April 2009-March 2010
43. Patient behaviour after pharmacist’s recommendation of cheaper alternative 43. in Hungary, 2010
44. Largest ATC categories in Slovakia by value (€ m), by insurance companies and 44. patient payments, Q4 2009
45. Share of generic and innovative drugs as a proportion of overall pharmaceutical 45. market in Slovakia, by value and volume, Q3 2009
46. Value (€ m) and y-o-y change in the Slovak generic drug market, 46. 2009-2013
47. Value (€ m) and y-o-y change in the Slovak innovative drug market, 47. 2009-2013
48. Best-selling ATC categories in Bulgaria, by volume, 200948.
49. Best-selling ATC categories in Bulgaria, by value, 200949.
50. Sales value (BGN m) of original and generic medicines in Bulgaria, 50. 2007-H1 2010
51. Sales volume (m packages) of original and generic medicines in Bulgaria, 51. 2007-H1 2010
52. Share of generic and innovative drugs as a proportion of overall pharmaceutical 52. market in Bulgaria, by value and volume, H1 2010
53. Value (€ m) and y-o-y change in the Bulgarian generic drug market, 53. 2007-2013
54. Value (€ m) and y-o-y change in the Bulgarian innovative drug market, 54. 2007-2013
55. Applications for SPCs filed and SPCs granted, pending and effective 55. in the Czech Republic, 2004-2009
56. Number of SPC applications in Hungary, 2004-200956.
57. Sales of Bisoprolol-based generic and innovative medicines in Bulgaria, 57. by value (BGN m), 2005-2010
58. Sales of Bisoprolol based generic and innovative medicines in Bulgaria, 58. by volume, 2005-2010
59. Sales of Clopidogrel-based generic and innovative medicines in Bulgaria, 59. by volume, 2005-2010
60. Sales of Clopidogrel-based generic and innovative medicines in Bulgaria, 60. by value (BGN m), 2005-2010
61. Sales of Indapamide-based generic and innovative medicines in Bulgaria, 61. by value (BGN m), 2005-2010
62. Sales of Indapamide-based generic and innovative medicines in Bulgaria, 62. by volume, 2005-2010
63. Sales of Quetiapine-based generic and innovative medicines in Bulgaria, 63. by value (BGN m), 2005-2010
64. Sales of Quetiapine-based generic and innovative medicines in Bulgaria, 64. by volume, 2005-2010
65. Average margins on non-reimbursed products and y-o-y change in Poland, 65. 2005-January-November 2010
66. NFZ spending on drug reimbursement and y-o-y change in Poland (PLN m), 66. 2003-2011
67. Value of drug reimbursement spending by form of reimbursement 67. in Poland, 2009
68. Volume of reimbursed medicines by form of reimbursement 68. in Poland, 2009
69. The drug substances used in therapeutic programmes generating the highest cost 69. for NFZ in Poland (PLN m), 2009
70. Share of NFZ’s expenditures on therapeutic programmes in Poland, 70. by condition, 2009
71. NFZ spending on drug therapy programmes and y-o-y change in Poland (PLN m), 71. 2005-2011
72. Ten most costly chemotherapy substances for NFZ (PLN m), 200972.
73. Distribution of medicines in the Czech Republic in accordance with price of 73. medicine, by value, Q2 2010
74. Distribution of medicines in the Czech Republic in accordance with price of 74. medicine, by volume, Q2 2010
75. Number of prescriptions for reimbursable and non-reimbursable drugs 75. in the Czech Republic (%), 2005-2008
76. Spending of Czech health insurers on prescription drug reimbursement (CZK m), 76. 2005-2009
77. Gross average retail markup for drugs in Romania, 200977.
78. CNAS spending on drug reimbursement and y-o-y change in Romania (RON m), 78. 2006-2009
79. Spending on drug reimbursement in Romania (RON m), 200979.
80. Share of CNAS spending on therapeutic programmes in Romania 80. (RON m), 2009
81. Consumers’ payment (RON per package) for selected best-selling Rx drugs 81. in Romania, 2010
82. Average Egis medicine price cuts in Hungary, 2009 and 201082.
83. Top 10 medicines in terms of most substantial reimbursement spending 83. in Hungary (HUF m), January-October 2010
84. Monthly reimbursement spending on Glivec, Remicade and Spiriva 84. in Hungary (HUF m), January-October 2010
85. Example calculation of the maximum price of an Rx medicine 85. in Slovakia, 2011
86. Spending on Clopidogrel-based generic and original medicine reimbursement 86. in Bulgaria (BGN m), 2005-2010
87. Spending on Bisoprolol-based generic and original medicine reimbursement 87. in Bulgaria (BGN m), 2005-2010
88. Spending on Indapamide-based generic and original medicine reimbursement 88. in Bulgaria (BGN m), 2005-2010
89. Spending on Quetiapine-based generic and original medicine reimbursement 89. in Bulgaria (BGN m), 2005-2010
90. Sales revenues of Egis ($ m) and their y-o-y growth in selected CE countries, 90. 2009/2010
91. Breakdown of Egis sales in CE countries, 2009/201091.
92. Egis spending on research and development (HUF m), y-o-y increase 92. and its share in company’s net sales, FY 2000/2001-2009/2010
93. Gedeon Richter ownership structure, September 201093.
94. Sales revenues of Gedeon Richter (€ m) and their y-o-y growth in selected CE 94. countries, Q1-Q3 2010
95. Breakdown of Gedeon Richter sales in CE countries, Q1-Q3 201095.
96. Share of original and generic drugs as a proportion of Gedeon Richter’s 96. total sales, H1 2010
97. Gedeon Richter spending on research and development (HUF m), y-o-y increase 97. and its share as a proportion of the company’s sales, 2000-Q3 2010
98. Krka ownership structure, September 201098.
99. Sales revenues of Krka (€ m) and their y-o-y growth in selected CE countries, 99. Q1-Q3 2010
100. Breakdown of Krka sales in CE countries, Q1-Q3 2010100.
101. Number of new marketing authorisations obtained by Krka for prescription 101. pharmaceuticals in Central European region, 2005-2009
102. Krka annual spending on research and development (€ m), y-o-y increase 102. and its share in company’s sales revenues, 2003-Q3 2010
103. Sandoz revenues (PLN m) and their y-o-y change in Poland, 2002-2009103.
104. Sandoz’s annual spending on research and development ($ m), y-o-y increase 104. and its share in company’s net sales, 2005-Q3 2010
105. Stada ownership structure, December 2010105.
106. Sales revenues of Stada (€ m) and their y-o-y growth in selected CE countries, 106. Q1-Q3 2010
107. Breakdown of Stada sales in CE countries, Q1-Q3 2010107.
108. Sales (€ m) of generic and branded drugs of Stada in selected CE countries, 108. Q1-Q3 2010
109. Stada annual spending on research and development (e m), y-o-y increase 109. and its share in company’s sales, 2001-Q3 2010
110. Teva’s annual spending on research and development ($ m), y-o-y increase 110. and its share in company’s revenues, 2001-Q3 2010
111. AstraZeneca sales on emerging markets, by product status, 111. by value, 2009
112. Best-selling AstraZeneca drugs in Poland, market share by value, 2009112.
113. AstraZeneca spending on research and development ($ m), y-o-y change 113. and its share as a proportion of the company’s revenues, 2004-2009
114. Bayer revenues and net profit in Poland (PLN m), 2004-2009114.
115. Bayer HealthCare spending on research and development (€ m), y-o-y change 115. and its share as a proportion of the company’s net sales, 2004-2009
116. Value of Europharm sales (€ m), 2004-2009116.
117. GlaxoSmithKline spending on research and development (£ m), y-o-y change and 117. its share as a proportion of the company’s turnover, 2001-2009
118. Novartis spending on research and development ($ m), y-o-y increase 118. and its share as a proportion of the company’s net sales, 2004-2009
119. Pfizer annual spending on research and development ($ m), y-o-y increase 119. and its share as a proportion of the company’s revenues, 2004-Q3 2010
120. Roche sales structure, by division, 2009120.
121. 2010121.
122. Roche sales in the Czech Republic (€ m) and their y-o-y change, 122. 2006-2009
123. Estimated sales of key Roche products in Romania, by value, 2009123.
124. Roche Pharmaceuticals annual spending on research and development (CHF 124. m), y-o-y increase and its share as a proportion of the company’s sales, 2004-H1 2010
125. Sanofi-Aventis ownership structure, January 2010125.
126. Sanofi-Aventis spending on research and development (€ m), y-o-y increase 126. and its share as a proportion of the company’s net sales, 2004-H1 2010
127. Top 10 domestic Polish pharmaceutical companies, by value (€ m), 127. July 2009-June 2010
128. Top 10 domestic Polish pharmaceutical companies, by volume (million pieces), 128. July 2009-June 2010
129. Revenues (RON m) and y-o-y change of Antibiotice, 2002-2010129.
130. Market share of foremost Bulgarian pharmaceutical manufacturers, 130. by value, 2009

List of tables

1. Annual average exchange rates used for this report (euro to national currency 1. unit), 2006-2010
2. The largest exporters of drugs from Romania, 2009-20102.
3. Top 10 best-selling drugs in Poland, by value (PLN m), 20093.
4. Top 10 best-selling innovative drugs in the Czech Republic, by value (CZK m), 4. Q1 2010
5. Top 10 best-selling innovative drugs in the Czech Republic, by value (CZK m), 5. Q2 2010
6. Top 5 best-selling generic drugs in the Czech Republic, by volume, Q1 20106.
7. Top 5 best-selling generic drugs in the Czech Republic, by volume, Q2 20107.
8. Top 10 best-selling pharmaceutical substances in the Czech Republic, 8. by value (CZK m), 2009
9. Top 10 best-selling pharmaceutical substances in the Czech Republic, 9. by volume, 2009
10. Fees for Supplementary Protection Certificates in the Czech Republic, 201110.
11. SPCs valid in the Czech Republic, December 201011.
12. Top 10 best-selling innovative drugs in Romania, by value, 2008-200912.
13. Top best-selling generic drugs in Romania, by value, 2008-200913.
14. Fees for Supplementary Protection Certificate in Romania, 201114.
15. Top 10 best-selling innovative drugs in Hungary, by value (HUF bn), 200915.
16. Fees for Supplementary Protection Certificate in Hungary, 201116.
17. SPC certificates to expire within the next five years in Hungary, 201017.
18. Top 10 best-selling innovative drugs in Slovakia, by value (€ m), 18. Q1-Q3 2010
19. Top four best-selling generic drugs in Slovakia, by value (€ m), Q1-Q3 201019.
20. Fees for supplementary protection certificate in Slovakia, 201120.
21. SPC certificates to expire within the next five years in Slovakia, 201021.
22. Top 10 best-selling innovative Rx drugs in Bulgaria, 22. by value (BGN m), 2009
23. Sales value and volume of Bisoprolol-based original and generic medicines 23. in Bulgaria, 2009-2010
24. Sales value and volume of Clopidogrel-based original and generic medicines 24. in Bulgaria, 2009-2010
25. Sales value and volume of Indapamide-based original and generic medicines 25. in Bulgaria, 2009-2010
26. Sales value and volume of Quetiapine-based original and generic medicines 26. in Bulgaria, 2009-2010
27. Fees for Supplementary Protection Certificate in Bulgaria, 201127.
28. Comparison of drug patent expiry and data exclusivity periods (years) 28. in the Central European countries analysed, 2011
29. Official retail margins for reimbursed drugs in Poland, 201129.
30. Five pharmaceutical substances generating highest reimbursement costs 30. in Poland, 2009
31. New drugs added to reimbursement lists in Poland, 30 December 201031.
32. New drugs added to reimbursement lists in Poland, 16 December 200932.
33. New drugs added to reimbursement lists in Poland, 16 March 200933.
34. Official margins for reimbursed drugs in the Czech Republic, 201134.
35. Drugs placed on and withdrawn from the reimbursement list 35. in the Czech Republic, November 2010
36. Drugs added to and withdrawn from the reimbursement list 36. in the Czech Republic, December 2010
37. Market shares of pharmaceuticals by price range in Romania, 200937.
38. Official wholesale margins for drugs in Romania, 201138.
39. Official retail margins and gross margins for drugs in the Romania, 201139.
40. Number of drugs on reimbursement lists in Romania, 200940.
41. Solidarity fees paid by pharmacies in Hungary and their correlation with quarterly 41. incomes from reimbursed drugs, 2011
42. Taxes and fees paid by manufacturers in Hungary, 2007-200942.
43. Official wholesale markups for reimbursed drugs in Hungary, 201143.
44. Official retail markups for reimbursed drugs in Hungary, 201144.
45. Results of the generic programme in Hungary, average price reduction and 45. number of drugs at reduced prices, February 2010-January 2011
46. Administrative fees for reimbursement procedure in Hungary, 201146.
47. New brands placed on the reimbursement list in Hungary, October 201047.
48. Changes in the reimbursement list in Hungary, by ATC category, 48. October 2010
49. New original and generic brands placed on the reimbursement list in Hungary, 49. September 2010
50. Changes in the reimbursement list in Hungary, by ATC category, 50. September 2010
51. New original and generic brands to appear on the reimbursement list in Hungary, 51. August 2010
52. Changes in the reimbursement list in Hungary, by ATC category, 52. August 2010
53. Official wholesale and retail margins for Rx medicines in Slovakia, 201153.
54. Comparison between July 2010 and October 2010 reimbursement lists 54. in Slovakia, in terms of patient co-payment (%)
55. Comparison between July 2010 and October 2010 reimbursement lists 55. in Slovakia, in terms of patient co-payment (€)
56. Comparison between April 2010 and July 2010 reimbursement lists in Slovakia, 56. in terms of patient co-payment (%)
57. Comparison between April 2010 and July 2010 reimbursement lists in Slovakia, 57. in terms of patient co-payment (€)
58. Official wholesale and retail margins for Rx drugs in Bulgaria, 201158.
59. Innovative and generic drugs introduced to and withdrawn from the Positive Drug 59. List in Bulgaria, November 2010
60. Innovative and generic drugs placed on Positive Drug List in Bulgaria, 60. October 2010
61. Innovative and generic drugs placed on Positive Drug List in Bulgaria, 61. September 2010
62. Actavis sales in selected CE countries, 200962.
63. Drugs launched by Egis in CE countries, 2009/201063.
64. Drugs launched by Egis in Hungary, 2009/201064.
65. Generic and innovative drugs launched by Gedeon Richter in selected CE countries 65. analysed, 2009
66. Selected Gedeon Richter clinical trials, December 201066.
67. Krka best selling drugs in selected CE countries, Q1-Q3 201067.
68. Sandoz sales in selected CE countries, 200968.
69. Teva clinical trials carried out in CE countries, December 201069.
70. AstraZeneca sales in selected CE countries, 200970.
71. Best-selling AstraZeneca medicines in Romania by value, 200971.
72. Selected AstraZeneca clinical trials carried out in CE countries, 72. December 2010
73. Bayer sales in selected CE countries, 200973.
74. Patent expiry date of selected Bayer key original products in European Union 74. countries, 2011
75. Bayer product pipeline development and selected clinical trials carried out 75. in the CE region, December 2010
76. GSK sales in selected CE countries, 200976.
77. Best-selling GlaxoSmithKline medicines in Romania by value, 200977.
78. Patent expiry date of selected GlaxoSmithKline key original products 78. in European Union countries, 2011
79. Selected GSK clinical trials carried out in CE countries, December 201079.
80. Novartis sales in selected CE countries, 200980.
81. Best-selling Novartis medicines in Romania, by value, 200981.
82. Best-selling Novartis medicines in Slovakia (€ m), Q1-Q3 201082.
83. Patent expiry date of selected Novartis key original products on major European 83. markets, 2011
84. Novartis product pipeline development and selected clinical trials carried out 84. in the CE region, December 2010
85. Pfizer sales in selected CEE countries, 200985.
86. Best-selling Pfizer medicines in Romania by value, 2009
87. Selected Pfizer clinical trials carried out in CE countries, December 201088.
88. Roche sales in selected CE countries, 200989.
89. Best-selling Roche medicines in Romania by value, 200990.
90. Best-selling Roche medicines in Slovakia (€ m), Q1-Q3 201091.
91. Data exclusivity of selected Roche key original products in European Union 92. countries, 2011
92. Roche product pipeline development and clinical trials carried out 93. in the CE region, December 2010
93. Sanofi-Aventis sales in selected CE countries, 200994.
94. Best-selling Sanofi-Aventis medicines in Romania by value, 200995.
95. Patent expiry date of selected Sanofi-Aventis key original products 96. in CEE countries, 2011
96. Sanofi-Aventis product pipeline development and clinical trials carried out 97. in the CE region, January 2011
97. Best-selling Servier medicines in Romania by value, 200998.
98. Best-selling Servier medicines in Slovakia (€ m), Q1-Q3 201099.
99. Top 10 leading pharmaceutical companies on the Polish pharmaceutical market, 100. by value market share, 2009
100. Selected leading innovative companies on the Czech pharmaceutical 101. market, 2009
101. Selected leading generic companies on the Czech pharmaceutical 102. market, 2009
102. Top 10 leading domestic companies on the Romanian pharmaceutical market, 103. by sales value (€ m), 2008-2009
103. Top 10 leading companies on the Romanian pharmaceutical market, 104. by sales value (€ m), H1 2010
104. Number of new products due to be launched in Romania, 2010-2012105.
105. Estimated results of Compania Farmaceutica Nationala in Romania, 2010106.
106. Top 10 leading companies on the Hungarian pharmaceutical market, 107. by sales value, 2009

Actavis
AstraZeneca
Bayer
Berlin-Chemie/Menarini
Egis
Gedeon Richter
GlaxoSmithKline
Krka
Novartis
Novo Nordisk
Pfizer
Polpharma
Ranbaxy
Roche
Sandoz
Sanofi-Aventis
Schering-Plough
Servier
Stada
Teva
Zentiva

and more...